Stage
Pre-prototype
No clinical validation, FDA clearance, or finished device is being claimed.
Measure bladder state, not wet fabric.
DryNight is a pre-prototype lower-abdomen patch concept for pediatric bedwetting. It is being designed to estimate bladder filling before wetness, cue the child privately, and involve caregivers only when useful.
Night loop concept
Pre-prototype interface for product review, not validated sensor output.
Mode
Child first
Cue threshold
72%
Estimate 48% Private cue first
Patch fit
Stable contact
Simulated
Signal
48% estimate
Review only
Cue mode
Child first
Private
Caregiver fallback stays quiet.
The wearer receives the first prompt. Caregiver escalation is configured only when useful.
01
Soft patch concept
02
Private cue path
03
Optional caregiver backup
Concept-stage only. Not clinically validated, FDA-cleared, or available for diagnosis, treatment, or medical decision-making.
First use case
Pediatric nocturnal enuresis
A narrow first wedge before any adult or older-adult expansion.
Technical risk
Overnight signal quality
Motion, posture, contact, power, comfort, false alerts, and useful lead time.
Development path
Focused validation
Test whether bladder filling can be estimated early enough to cue before voiding.
Proof before promotion
A leaner site should make the diligence path obvious.
The homepage should not try to sound larger than the company is. It should show the product hypothesis, the current stage, and the evidence gates that would make DryNight worth building.
Stage
Pre-prototype
No finished device, clinical validation, or FDA clearance is being claimed.
First claim
Pre-void cue feasibility
The first test is whether bladder filling can be estimated early enough to cue before wetness starts.
Standard
Evidence before promotion
Published precedent supports feasibility work. DryNight still has to earn its own performance data.
Night loop
A caregiver sees the plan. The wearer gets the first private cue.
The product is being designed around dignity first: a child, adult, or older adult gets a private signal before a caregiver is brought in. The hardware path can change; these product standards should not.
One night, three signals
Concept experience, not device proof
DryNight night loop
Sense locally. Cue privately. Escalate only when useful.
01 Sense
Soft abdomen patch concept
Local bladder-filling estimate, still under feasibility testing.
02 Private cue
Wearer gets the first cue
A private haptic prompt before any public alert.
03 Caregiver
Caregiver only if needed
A configured alert when the private cue is not enough.
- 01
Before bed
Place the patch once
The lower-abdomen patch has to be soft, cordless, and stable enough that setup does not become a nightly argument.
- 02
During sleep
Estimate bladder filling locally
Raw sensing should stay close to the device while the system looks for a conservative threshold, not a diagnostic conclusion.
- 03
First cue
Cue the wearer privately
The cue should be private and gentle before a public alarm or caregiver escalation is considered.
- 04
Escalation
Bring in help only when needed
Caregiver alerts should be configurable, minimal, and reserved for moments when the private cue alone is not enough.
Product standards
-
Private by default
No loud bedroom alarm as the default interaction.
-
Evidence before promotion
No performance number appears until the study design can defend it.
-
Comfort before dashboards
A family will not use a better signal if the device is hard to wear.
Alert logic
Quiet monitoring Actionable cue
The wearer gets the first prompt. Caregiver escalation is a configured backup, not the default emotional experience.
Validation roadmap
The next 90 days should reduce technical risk, not inflate the story.
DryNight becomes more credible when each stage answers a concrete proof question. The roadmap below is intentionally narrow because the company is pre-prototype and not clinically validated.
DryNight is not FDA-cleared, not clinically validated, and not available for diagnosis, treatment, or medical decision-making. The current work is feasibility, human factors, and study design.
0–30 days
Lock the product claim and evidence file
Define the first claim as pre-void cue feasibility, not bedwetting treatment.
- Write the intended-use boundary and prohibited claims list.
- Complete a source map for enuresis care, wetness alarms, and bladder-monitoring literature.
- Define the minimum useful lead-time endpoint before any prototype study.
Decision gate Can the company explain exactly what it is testing without implying that the device already works?
31–60 days
Choose the first sensing experiment
Compare candidate sensing paths against the realities of overnight pediatric wear.
- Specify ultrasound and bioimpedance bench tests, including motion and contact-loss cases.
- Define patch placement, adhesion, comfort, power, and thermal constraints.
- Create a failure-mode table for false cues, missed cues, skin contact loss, and parent fatigue.
Decision gate Is there a signal path worth prototyping on the body?
61–90 days
Prepare human-factors and feasibility work
Turn the technical experiment into a study-ready product program.
- Draft a repeated-night usability protocol for comfort, adherence, and setup burden.
- Recruit pediatric continence, wearable sensing, regulatory, and manufacturing advisors.
- Build a funding memo tied to signal feasibility, cue lead time, and usability gates.
Decision gate Is DryNight ready for a controlled prototype build and clinician-reviewed feasibility plan?
Risks to de-risk first
The company should earn confidence one failure mode at a time.
- 01 Overnight signal quality
- 02 Patch placement drift
- 03 Motion artifacts
- 04 Sleep posture
- 05 Skin contact and comfort
- 06 Power and battery limits
- 07 False alarms and missed cues
- 08 Useful lead time before voiding
- 09 Parent fatigue
- 10 Pediatric safety and usability
Market focus
Start with the child who hides the sheets.
DryNight starts with pediatric nocturnal enuresis because the pain is specific, recurring, and poorly served by existing consumer tools. Adult incontinence remains a relevant expansion path, but the first proof point has to be narrow.
Primary market
Pediatric nocturnal enuresis.
The first user is a child who can sleep through a full bladder and a parent trying to help without shame. The initial product experience should be private, comfortable, and narrow enough to test rigorously.
- Market signal
- Families already buy alarms, mattress protection, and repeated workarounds
- Validation path
- Bench testing, overnight usability, and pediatric continence input
The founder
I wet the bed until I was twelve.
DryNight is founder-led and early. The right kind of credibility here is simple: why this founder cares, what the public record supports, and what none of those references prove about this device yet.
Founder background can explain operator context. It does not substitute for product validation, pediatric evidence, or regulatory review.
I grew up in Cameroon. My grandparents tried everything: raw okra, anthills, every remedy the village knew. Nothing worked. I stopped going to boarding school so no one would find out. I became the cleanest, most driven student I could be, because I was convinced no one could ever know what I was hiding at night.
Now my nine-year-old son wets the bed every night. His is more severe than mine. I refuse to shame him the way I was shamed. But the best alarms on the market still have cords, still detect moisture after the fact, still fail him.
So I started building what I wish I had. DryNight begins with my son, but the standard is broader: a child should not have to be wet before the system understands that help is needed.
Ndansi Elvis Nukam
Founder & CEO, DryNight
About the founder
DryNight is deliberately not using a long credential stack here. The public references above help a parent, clinician, or investor understand the founder's operating context without turning biography into a substitute for evidence.
More detailed product language, advisor names, and institutional relationships should appear only once they are current, verified, and directly relevant to what the company is ready to say.
Founder writing
Writing that explains the mission before the product.
Beyond Blames is the DryNight companion book. Elvis has also published earlier work on hope, service, and personal agency. The point is not to turn the site into a bookshelf. It is to show that DryNight comes from a longer public voice about dignity, care, and access.
Forthcoming companion book
Beyond Blames
A book about bedwetting, childhood shame, and what families can do differently. It gives the product a human foundation without replacing the evidence DryNight still has to earn.
Publishes May 23, 2026
Read the DryNight book page →Earlier published book
The Obama in You
A 2022 book by Elvis Ndansi on hope, service, mentorship, and personal agency. Public book listings identify the full title as The Obama in You: Using Hope to Power the Giant Within.
Published in 2022
View public book listing →Evidence room
A credible company starts with a credible proof plan.
DryNight earns attention by being precise. The evidence room explains why the idea is plausible, where the first risk sits, and what proof would move the company from concept to funded medical-device program.
Problem reality
Care realityThe first proof is not technical. The first proof is that timing, dignity, and caregiver burden matter enough to justify a better product.
-
Bedwetting is common in school-age children and often resolves gradually rather than immediately.
-
Most household alarms start when wetting begins, not when the bladder first becomes actionable.
-
Families need earlier information and less public interruption, not a louder signal after wetness has already reached clothing or bedding.
Technical precedent
Published precedentOutside literature makes the sensing thesis serious enough to test. It does not remove the need for DryNight to prove its own hardware, software, and user experience.
-
Wearable lower-abdomen ultrasound detected full bladders before voiding in 90% of a 30-child urodynamic cohort aged 6 to 12.
-
Overnight home monitoring of natural nocturnal bladder filling was feasible in children with monosymptomatic nocturnal enuresis on 83% of monitored nights without disturbing sleep.
-
Noninvasive bladder monitoring is an active research area across ultrasound, bioimpedance, optical sensing, and flexible ultrasonic devices.
Product thesis
Company thesisDryNight is taking a clear position: the winning product is not only a sensor. It is a private timing system that fits the home.
-
The first wedge is a soft lower-abdomen patch, a private wearer cue, and optional caregiver escalation.
Company thesis, validation milestone
-
The first product milestone should be narrow: timely pre-void cueing before wetness starts.
Company thesis, validation milestone
-
The same timing problem can later support adult, older-adult, and caregiver workflows once the pediatric proof point is earned.
Company thesis, validation milestone
Validation milestones
Next proofThis is the work that turns a strong idea into an investable medical-device program.
-
Select the sensing architecture that survives body-size variation, sleep position, motion, adhesion, and power constraints.
-
Define an actionable threshold that balances missed cues, false cues, wearer comfort, and caregiver burden.
Company thesis, validation milestone
-
Run repeated-night usability and a clinician-reviewed pilot before expanding the market story.
Investor diligence
Why is this a company, not just a feature?
The unmet need is not a cleaner wetness alarm. It is earlier, quieter, more private timing. A product that can identify a useful pre-void window has a different value proposition for families, pediatric continence care, older-adult care, and long-term caregiver workflows.
What makes the technical thesis credible?
The literature already includes noninvasive bladder monitoring, wearable ultrasound work, pediatric urodynamic testing, and overnight home monitoring in children with nocturnal enuresis. That is enough to justify serious feasibility work, especially if DryNight stays focused on a narrow first milestone.
Where is the first technical risk?
Signal quality under real overnight conditions. The system must handle motion, sleep position, body variation, sensor coupling, adhesion, battery life, and the difference between a useful trend and noise.
What would make the next financing round credible?
A credible round should be tied to specific de-risking: bench signal quality, a wearable form factor, repeated-night comfort, a defensible cue threshold, and a clinician-reviewed pilot protocol. Those milestones are concrete enough for investors, advisors, and device partners to pressure-test.
Why keep the first milestone narrow?
Because a narrow milestone can be tested, funded, and defended. Pediatric nocturnal enuresis gives DryNight a specific first wedge. Adult and older-adult continence workflows become stronger expansion paths after the signal, comfort, and cue logic are validated.
What the company needs
Clinical and study design
DryNight needs advisors who can turn the first milestone into a study plan that matters clinically and commercially.
- 01 Pediatric urology, continence, sleep, and behavioral-health input on patient selection and meaningful endpoints
- 02 Feedback on what counts as clinically useful pre-void notice versus noise
- 03 Early design help for feasibility, human-factors, and pilot study protocols
Wearable sensing and manufacturing
The hardware path has to be comfortable, low-power, manufacturable, and strong enough for repeated overnight wear.
- 01 Wearable ultrasound, bioimpedance, signal processing, low-power electronics, and patch mechanics expertise
- 02 Advice on coupling, motion artifacts, overnight adhesion, battery tradeoffs, and manufacturable form factors
- 03 Reality checks on whether a pediatric overnight product can be comfortable enough for repeated use
Capital and commercialization
The business path should finance the right proof, protect the first milestone, and keep the broader market in view.
- 01 Regulatory guidance on intended use, performance language, and the right sequence of risk-reduction work
- 02 Quality-system and manufacturing advice appropriate for an early medical-device program
- 03 Investors and operators who fund evidence milestones, not vanity waitlist metrics
Foundational citations
-
Lauters et al., 2022
Enuresis in Children: Common Questions and Answers
Supports burden, spontaneous resolution, and the current standard of alarms plus desmopressin for many children.
-
NICE CG111, 2010
Bedwetting in under 19s: initial treatment
Clarifies that alarms detect when wetting starts, often require sustained family effort, and are not ideal for every household.
-
Hafid et al., 2023
State of the Art of Non-Invasive Technologies for Bladder Monitoring: A Scoping Review
Summarizes ultrasound, optical, and bioimpedance approaches for non-invasive bladder monitoring and highlights the field's current limits.
-
van Leuteren et al., 2018
Validation of a wearable ultrasonic bladder monitor in children during urodynamic studies
Pediatric urodynamic-room study in 30 children aged 6 to 12. A wearable lower-abdomen ultrasound sensor detected the full bladder before voiding in 90% of patients (27 of 30), with strong correlation between estimated and infused volumes.
-
Kwinten et al., 2020
Continuous home monitoring of natural nocturnal bladder filling in children with nocturnal enuresis: a feasibility study
Overnight home feasibility study in 15 children aged 6 to 12 with monosymptomatic nocturnal enuresis. A wearable abdominal ultrasound monitor successfully tracked natural nocturnal bladder filling on 83% of nights without disturbing sleep.
-
Toymus et al., 2024
An integrated and flexible ultrasonic device for continuous bladder volume monitoring
Shows that wearable ultrasound bladder sensing is technically plausible in research settings, while still distinct from a validated pediatric product.
Team
One founder, one company, one first question.
DryNight is Elvis's company. The team will grow around the work. The seats are named plainly so it is clear where the company is, what expertise is still missing, and what support is exploratory rather than committed.
Highest-priority gaps
- 01 Pediatric urology or continence-study advisory leadership
- 02 Biomedical sensing and wearable engineering
- 03 Regulatory affairs (medical devices)
- 04 Quality, manufacturing, and supply-chain planning
What is exploratory versus committed
These are areas of active exploration, not announced partnerships or signed advisors. Names will appear only when there is actual permission and commitment.
- Wearable engineering and sensor architecture conversations
- Pediatric continence research-site discovery
- Long-term-care workflow and reimbursement learning
Contact
Help shape the product before claims are made.
DryNight needs grounded input from families, clinicians, engineers, care operators, and investors before the company turns the concept into a device. Use this form for feedback, research conversations, partnership ideas, manufacturing leads, or funding conversations.
Best-fit outreach right now: families with lived experience, pediatric continence clinicians, research partners, wearable sensing engineers, regulatory operators, manufacturing partners, and investors who care about feasibility discipline more than early polish.
What happens next
01
Route the note
We use your role and interest to separate family feedback, clinical conversations, manufacturing leads, and investor outreach.
02
Follow up only when relevant
The goal is a useful conversation, not a mailing list.
03
Keep the conversation useful
DryNight is not collecting medical advice requests or private patient details through this form.